Abstract 454P
Background
T-DXd is approved as 2L or later treatment for HER2-positive gastric cancer in several countries and is considered emetogenic. Nausea and vomiting affect significantly patient quality of life, leading to poor compliance with further treatment. Therefore, we sought to identify the optimal combination of antiemetic prophylaxis with T-DXd.
Methods
This study was a multicenter, randomized, open-label, non-comparative, Ph2 study to investigate optimal antiemetic prophylaxis for Japanese patients (pts) with gastric cancer treated with T-DXd. The pts were randomized to a doublet regimen (DxR, dexamethasone and palonosetron) or a triplet regimen (TxR, aprepitant in addition to doublet regimen) at a ratio of 1:1; stratified by gender, gastrectomy status, and study site. T-DXd admiration was started at 6.4 mg/kg and the antiemetic prophylaxis was administered from day 1 up to day 5. The primary endpoint was antiemetic complete response (CR, defined no emetic event and no rescue drug) rate to assess control emesis based on patient reported outcomes for 21 days. CR rate in acute phase (0-24hr) and delayed phase (2-21d) were evaluated as a secondary endpoint. With 29 pts per arm, the primary analysis considered a regimen promising if either arm had ≥18 CRs.
Results
A total of 58 pts were eligible for this analysis. Three pts were discontinued follow-up (2 pts in DxR, 1 pt in TxR). Both antiemetic CR rate for 21 days (overall) and CR rate in delayed phase were 41.4% (12/29) for DxR and 37.9% (11/29) for TxR. The antiemetic CR rate in acute phase was 86.2% (25/29) in both regimens. The median first emetic event occurred at 3 day in both regimens.
Conclusions
Both antiemetic prophylaxis regimens did not meet the prespecified antiemetic CR rate. This study, which used patient reported outcome to assess emetic events, has resulted in a higher rate of emetic events compare to monitoring by physicians reported in previous studies. Given the study design and small sample size, further research may help to fully characterize nausea and vomiting with T-DXd in gastric cancer pts.
Clinical trial identification
jRCTs031200336.
Editorial acknowledgement
Legal entity responsible for the study
Yokohama City University Hospital, Epidemiological and Clinical Research Information Network (ECRIN), and Daiichi Sankyo Co., Ltd.
Funding
Daiichi Sankyo Co., Ltd.
Disclosure
K. Oba: Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo; Financial Interests, Personal, Other, IDMC member: Eisai, Ono pharmaceutical co, Janssen. K. Nishikawa: Financial Interests, Personal, Invited Speaker, Lecture fee: Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eli Lilly, MSD, Ono, Taiho, Yakult. H. Maeda: Financial Interests, Personal, Invited Speaker: Tsumura Co; Financial Interests, Personal, Writing Engagement: Igaku-shoin; Non-Financial Interests, Personal, Other, journal editor: Annals of cancer research and therapy; Non-Financial Interests, Personal, Other, research advisory: Japanese foundation of multidisciplinary cancer treatment; Non-Financial Interests, Personal, Other, editorial board: Japanase society of human cells. A. Makiyama: Financial Interests, Personal, Invited Speaker: Eli Lilly, Taiho, Ono, Daiichi Sankyo, Bristol Myers Squibb. T. Oshima: Financial Interests, Personal, Invited Speaker: Taiho, Astellas; Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Other, research grant: Taiho, Kyowa Kirin, Chugai, Nihon kayaku. A. Katayama: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. K. Shiosakai: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract